GleamWall
中文EN

GLUC Glucose Health, Inc.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1420108 · Fiscal year ends 12/31

Financial factors as of 2017-09-30 (2017Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-70.6%
TTM net income YoY73.8%
TTM EPS YoY—
Revenue 3-yr CAGR237.6%
Net income 3-yr CAGR—

Margins

Gross margin65.4%
Operating margin-36.8%
Net margin-96.5%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-241.9%
ROIC (approx.)—
Asset turnover2.51x

Leverage & solvency

Liabilities / assets1,717.4%
Debt / equity—
Current ratio0.06x
Interest coverage-0.29x

Cash quality & payout

Operating cash flow / net income0.20x
Accruals ratio-192.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2017Q32017-09-302017Q22017-06-302017Q12017-03-312016Q4*2016-12-312016Q32016-09-302016Q22016-06-302016Q12016-03-312015Q4*2015-12-31
Income statement
Revenue$23,783$34,046$15,111$15,190$2,110$295,809$120$1,640
Cost of revenue$790$272$14,638$14,804$4,734$274,464$60$1,585
Gross profit$22,993$33,774$473$386-$2,624$21,345$60$55
SG&A expense$4,694$7,557$12,490$6,798$36,356$5,767$2,917$79,222
Operating income$4,635$16,077-$28,313-$24,848-$55,556$6,032-$12,275-$14,913
Interest expense$5,720$5,096$696$99,232$105,263$93,402$16,988$21,449
Pretax income$18,769$49,258-$29,009-$124,080-$160,819-$87,370-$29,263-$46,798
Net income$18,769$49,258-$29,009-$124,080-$160,819-$87,370-$29,263-$46,798
EPS (basic)0.000.01-0.01—-0.06-0.03-0.01—
EPS (diluted)————————
Balance sheet
Cash & equivalents$16,636$18,313$9,008$20,542$23,639$27,773$1,946$2,055
Receivables$9,105$8,795$9,632$11,724$11,742$168,346$3,150$3,150
Inventory$0$0$0—$6,418$8,310$8,310$8,370
Current assets$26,158$27,108$18,640$32,905$43,662$206,809$51,332$15,107
Total assets$26,353$27,318$18,865$33,145$43,962$207,109$51,632$15,407
Current liabilities$452,585$476,607$542,431$528,592$417,594$423,804$454,763$403,226
Total liabilities$452,585$476,607$542,431$528,592$417,594$423,804$454,763$403,226
Shareholders' equity-$426,232-$449,289-$523,566-$495,447-$373,632-$216,695-$403,131-$387,819
Shares outstanding4.52M3.98M3.42M3.31M3.03M2.75M2.54M2.45M
Cash flow statement
Operating cash flow-$1,677-$695-$11,534-$3,347$61,866-$49,173-$48,609-$9,239
Investing cash flow———————$0
Financing cash flow$0——$0-$66,000$75,000$48,500$2,500
Stock-based compensation———$0$1,875———

Free plan shows the latest 8 periods; Pro shows all 29 🔒

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.